ADmit Therapeutics
ADmit Therapeutics is a Barcelona-based biotech that sells the MAP-AD Test, a CE-marked blood-based IVD using mitochondrial DNA methylation and machine learning to predict progression from Mild Cognitive Impairment to Alzheimer's dementia, serving neurologists, memory units, and pharmaceutical trial sponsors in the EU and US.
- Company typePrivate
- Founded2017
- HeadquartersBarcelona, Spain
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ADmit Therapeutics does
ADmit Therapeutics is a Barcelona-based biotechnology company founded in 2017 as a spin-off from IDIBELL (Bellvitge Biomedical Research Institute) that has developed the MAP-AD Test, a CE-marked blood-based in vitro diagnostic for prognostic assessment of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia in patients aged 55 to 85. The test combines Next Generation Sequencing analysis of proprietary mitochondrial DNA methylation biomarkers with the patient's ApoE genotype, age, and CDR-SOB neuropsychological score, processed through a Machine Learning algorithm to produce a prognostic output. The platform's distinguishing feature is that mitochondrial methylation-based prognosis operates independently of amyloid and tau pathology, enabling stratification of amyloid-negative individuals, and links bioenergetic decline to cognitive trajectory.
The company operates a CAP/CLIA-accredited, ISO 13485-certified laboratory in the Barcelona metropolitan area (Sant Feliu de Llobregat / Esplugues de Llobregat) that performs the MAP-AD test, and it sells through two commercial channels: per-test diagnostic services to neurologists, memory units, and healthcare systems, and epigenetic services to pharmaceutical companies for patient stratification in Alzheimer's clinical trials. It secured CE marking under IVDR (EU 2017/746) in September 2025 and CLIA certification from US CMS in December 2025, becoming the first Spanish CAP/CLIA-accredited laboratory and enabling both EU and US commercialization. The MAP-AD Test is supported by clinical validation published in iScience (Cell Press) and a patent application on the underlying mitochondrial DNA methylation biomarkers.
ADmit has raised approximately €10 million since inception from a mix of venture and public investors, anchored by Clave Capital (lead of the €5.4M round in October 2023), the European Innovation Council Fund, the Alzheimer's Drug Discovery Foundation, Bstartup10, Ship2B, EIT Health, the Spanish Ministry of Science, Innovation and Universities, WA4STEAM, Lavanda Ventures, and GENESIS Ventures, alongside H2020 program funding (grant 960327). The company runs with a 1–10 person core team supplemented by a high-caliber Medical and Scientific Advisory Board that includes Russell Swerdlow, Howard Fillit, Jordi Gascón, and Ramón Reñé.
ADmit Therapeutics firmographics
Firmographics- Name
- ADmit Therapeutics
- Legal name
- ADMIT THERAPEUTICS SL
- Website
- https://admit-therapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ADmit Therapeutics is a Barcelona-based biotech that sells the MAP-AD Test, a CE-marked blood-based IVD using mitochondrial DNA methylation and machine learning to predict progression from Mild Cognitive Impairment to Alzheimer's dementia, serving neurologists, memory units, and pharmaceutical trial sponsors in the EU and US.
- Ownership category
- akta.pro rank
ADmit Therapeutics industry classification
Industry- Product category
- Alzheimer's Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Epigenomics & Chromatin Profiling Services (HLAGANAF)
Keywords
Where ADmit Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
ADmit Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- MAP-AD Test Services: Commercialization of the MAP-AD blood test for prognosis of Alzheimer's dementia progression. The test is offered to healthcare providers and patients through the company's CAP/CLIA accredited laboratory.
- Epigenetic Services to Pharmaceutical Companies: Provides epigenetic services to pharmaceutical companies for conducting clinical trials involving AD patients in early stages of the disease, optimizing patient recruitment for clinical trials.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
ADmit Therapeutics product offering
Product offeringCore offering
ADmit Therapeutics develops and commercializes the MAP-AD Test, a qualitative CE-marked in vitro diagnostic blood test for prognosis of progression from Mild Cognitive Impairment to Alzheimer's disease dementia in patients aged 55-85. The test analyzes novel mitochondrial DNA methylation biomarkers combined with ApoE genotype, age, and CDR-SOB scores using Next Generation Sequencing and a proprietary AI-algorithm. The company also offers epigenetic services to pharmaceutical companies for clinical trial patient stratification.
Product overview
ADmit Therapeutics offers the MAP-AD Test system, a disruptive in vitro prognostic solution for Alzheimer's disease. The system consists of three integrated components: the MAP-AD Test (core product - a CE-marked blood test), MAP-AD Software (for data processing and prognosis generation), and MAP-AD Oligos (laboratory reagents). Together they provide a holistic analysis combining mitochondrial DNA methylation biomarkers with ApoE genotype, age, and neuropsychological assessment to predict progression from Mild Cognitive Impairment to Alzheimer's dementia.
Differentiator
Problem solved
Functional benefit
Brands
- MAP-AD Test: A CE-marked in vitro prognostic solution based on the first mitochondrial DNA epigenetic biomarker for Alzheimer's dementia, employing Next Generation Sequencing and Machine Learning techniques. The test predicts progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Products and services
- MAP-AD Test A qualitative in vitro diagnostic blood test for prognosis of progression from Mild Cognitive Impairment to Alzheimer's disease dementia in patients aged 55-85 years. Uses mitochondrial DNA methylation biomarkers combined with ApoE genotype, age, and neuropsychological assessment (CDR-SOB).
- MAP-AD Software Software component of the MAP-AD Test that securely processes patient data, integrating mitochondrial biomarker data from blood sample analysis together with clinical data (ApoE genotype, age, CDR-SOB) to provide prognosis of progression to dementia due to Alzheimer's disease.
- MAP-AD Oligos Oligonucleotide reagents used in laboratory analysis of blood samples for the MAP-AD Test, enabling the detection and measurement of mitochondrial DNA methylation biomarkers.
- Epigenetic Services for Pharmaceutical Clinical Trials Epigenetic services provided to pharmaceutical companies for conducting clinical trials involving AD patients in early stages of the disease, optimizing patient recruitment and stratification for clinical trials.
Quantifiable outcome
- Blood biomarker published in iScience (Cell Press) validates mitochondrial DNA methylation as predictor of Alzheimer's dementia progression in MCI patients
Companies that use ADmit Therapeutics
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
ADmit Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
ADmit Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- IDIBELL (Bellvitge Biomedical Research Institute)coreADmit Therapeutics was founded in 2017 as a spin-off from IDIBELL. The company originated from research conducted at this institute, and maintains ongoing collaboration for validation studies and research.
- Bellvitge University HospitalcoreLed by neurologist Jordi Gascón (co-founder) for observational clinical study. Head of Neurology and Memory Unit involved in validation of MAP-AD Test. Research collaboration ongoing.
- Hospital Clínic de BarcelonaminorParticipating center in the international collaborative study for MAP-AD Test validation. Major teaching hospital in Barcelona.
- Hospital de la Santa Creu i Sant PauminorParticipating center in the international collaborative study for MAP-AD Test validation.
- CITA-Alzheimer FoundationminorParticipating center in the international collaborative study for MAP-AD Test validation. Foundation focused on Alzheimer's research.
- University of Washington (Knight Alzheimer Disease Research Center)minorUS-based biorepository collaborator providing samples for MAP-AD Test validation study. Prestigious Alzheimer's research center.
- Australian Imaging, Biomarker and Lifestyle StudyminorInternational biorepository collaborator providing samples for MAP-AD Test validation study. Major Australian research initiative for Alzheimer's biomarkers.
- Consorcio Sanitari IntegralminorParticipating center in the international collaborative study for MAP-AD Test validation.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
ADmit Therapeutics competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based test for amyloid detection in Alzheimer's, and is expanding into prognostic biomarker services. It is the closest direct competitor to ADmit Therapeutics in the AD blood-based diagnostics category.
- ALZpath: ALZpath developed a blood-based p-tau217 assay for Alzheimer's detection and is commercializing through diagnostic partners. It competes with ADmit in the AD blood-test category, although with a different biomarker mechanism.
- Diadem srl: Diadem developed AlzoSure Predict, a blood-based prognostic test predicting progression to Alzheimer's dementia. It is the most direct competitor in MCI-to-AD prognosis, addressing the same clinical question as MAP-AD.
Broad incumbents
- Fujirebio: Fujirebio (H.U. Group) markets Lumipulse assays for Alzheimer's biomarkers (p-tau217, Aβ42/40) on automated immunoassay platforms, leveraging established hospital sales channels and is a major incumbent in AD blood-based diagnostics.
- Roche Diagnostics: Roche markets the Elecsys AD CSF assays and is developing blood-based AD biomarker tests, leveraging its global installed base in hospital laboratories. It is a broad incumbent that could move into ADmit's prognostic segment at scale.
- Sysmex Corporation: Sysmex is a major in-vitro diagnostics company with a growing portfolio in neurodegenerative disease biomarkers, including AD blood tests, leveraging extensive hospital channel reach across Asia and Europe.
Emerging players
- Quanterix: Quanterix provides ultra-sensitive Simoa biomarker measurement technology used in AD research and is expanding into clinical diagnostic applications. It is comparable to ADmit in target biomarker area, although focused on platform/tools rather than a single prognostic test.
- MagQu Co., Ltd. MagQu develops immunomagnetic reduction-based blood tests for Alzheimer's and Parkinson's disease biomarkers. It is an emerging AD diagnostics player pursuing a similar blood-based prognostic and diagnostic strategy.
Regional players
- Araclon Biotech: Araclon Biotech is a Spanish biotech developing ABtest assays for amyloid-beta detection as AD biomarkers. It is a regional (Spain-based) peer in the AD diagnostics space and a potential local partner or competitor.
Others
- Bio-Techne: Bio-Techne supplies proteomic biomarker assays, ELISA kits, and research reagents used in Alzheimer's research and diagnostics. It is an adjacent peer serving the AD biomarker ecosystem with tools and assays rather than a direct prognostic test.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ADmit Therapeutics social profiles
Digital presenceADmit Therapeutics compliance and trust
Trust signalCompliance4 records
ADmit Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADmit Therapeutics leadership team
Management profileNumber of profiles
Profiles16 records
ADmit Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADmit Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADmit Therapeutics
What does ADmit Therapeutics do?
ADmit Therapeutics develops and commercializes the MAP-AD Test, a qualitative CE-marked in vitro diagnostic blood test for prognosis of progression from Mild Cognitive Impairment to Alzheimer's disease dementia in patients aged 55-85. The test analyzes novel mitochondrial DNA methylation biomarkers combined with ApoE genotype, age, and CDR-SOB scores using Next Generation Sequencing and a proprietary AI-algorithm. The company also offers epigenetic services to pharmaceutical companies for clinical trial patient stratification.
Is ADmit Therapeutics a public or private company?
ADmit Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was ADmit Therapeutics founded?
ADmit Therapeutics was founded in 2017. It employs 1 to 10 people.
Where is ADmit Therapeutics based?
ADmit Therapeutics is headquartered in Barcelona, Spain, in the Europe region.
How does ADmit Therapeutics make money?
Two revenue lines are on record. MAP-AD Test Services are the primary driver. The others are epigenetic Services to Pharmaceutical Companies.
Who are ADmit Therapeutics's main competitors?
Direct peers on record are C2N Diagnostics, ALZpath and Diadem srl. Broad incumbents are Fujirebio, Roche Diagnostics and Sysmex Corporation. Emerging players are Quanterix and MagQu Co., Ltd.. Araclon Biotech is listed as a regional player. Bio-Techne is listed as an others.
Does ADmit Therapeutics have an API?
No public API is recorded for ADmit Therapeutics.
What industry is ADmit Therapeutics in?
ADmit Therapeutics's product category is Alzheimer's Diagnostics. Its primary akta.pro industry code is HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.